Pfizer

Pfizer is the world's largest pharmaceutical company by revenue, headquartered in New York and founded in 1849. It discovers, manufactures, and commercialises medicines and vaccines across oncology, immunology, rare disease, cardiology, and infectious disease. Pfizer's revenues reached $58.5bn in 2024, though they remain below the $100bn+ peak driven by COVID-19 vaccine sales. Its pipeline is one of the largest in pharma, with dozens of late-stage assets across therapeutic areas. Pfizer operates a significant corporate venturing and strategic investment Arm through Pfizer Ventures.

Pfizer joined CellCentric's £170m Series D in May 2026 as a strategic investor alongside the lead Venrock Healthcare Capital Partners, Fidelity, Sofinnova Partners, and others. CellCentric is developing inobrodib, a first-in-class p300/CBP inhibitor targeting multiple myeloma and prostate cancer — areas where Pfizer has existing commercial franchises. Pfizer's strategic co-investment (as distinct from a pure-financial position) signals potential interest in the asset as a business development or licensing candidate, though no commercial arrangement was disclosed at the time of the round.